This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Researchers from Mass General Brigham and collaborating institutions have developed a non-invasive approach to manipulate cardiac tissue activity by using light to stimulate an innovative ink incorporated into bioprinted tissue. Their goal is to develop a technique that can be used to repair the heart.
Amarin’s Vazkepa cardiology drug has been backed by the UK’s drugs regulator, following approval in Europe at the end of March. . Marketing authorisation of icosapent ethyl comes after a decade of designing and conducting evidence-based cardiovascular clinical outcomes research.
Food and Drug Administration (FDA) plays a pivotal role in fostering the development of treatments for rare diseases through its Orphan Products Grants Program. Each year, FDA selects a limited number of clinical trials to fund to help sponsors pursue development of medical products for rare diseases and advance their field.
Tom Zhang, PhD, Chief Scientific Officer, Large Molecule Bioanalysis Revolutionizing Therapeutic Development with Cutting-Edge Bioanalysis Automation Cutting-edge advancements in bioanalysis (BioA) and drug R&D are reshaping the future of preventative and interventional care, but how do we harness these to their fullest potential?
A research team from Wake Forest University School of Medicine has developed an open-source, web-based application that allows users to generate customized hypertension statistics using National Health and Nutrition Examination Survey (NHANES) data.
Using machine learning and clinical data from electronic health records, researchers at the Icahn School of Medicine at Mount Sinai in New York constructed an in silico, or computer-derived, marker for coronary artery disease (CAD) to better measure clinically important characterizations of the disease.
Rytis Maskeliūnas, a researcher at KTU's Faculty of Informatics, Lithuania together with an international team, has developed an app that will teach how to take care of a person who has suffered a stroke in a virtual environment. It is a condition that usually leaves the patient disabled, often requiring constant care.
LUCA Science Announces Joint Research With Division of Cardiology, Field of Internal Medicine, Nagoya University Graduate School of Medicine on the Development of Mitochondrial Therapy for Myocardial Infarction (Cardiac Ischemic-reperfusion Injury) LUCA Science Announces Joint Research With Division of Cardiology, … Continue reading →
Smidt Heart Institute Chair of Cardiology presents new findings at American Heart Association Scientific Sessions Credit: Photo by Cedars-Sinai LOS ANGELES (Nov.
Patients with severe COVID-19 requiring mechanical ventilation are 16 times more likely to develop ventricular tachycardia within six months compared to their peers without severe infection, according to research presented at EHRA 2023, a scientific congress of the European Society of Cardiology (ESC).
… Pfizer told employees it plans to pull back on early-stage research into treatments for rare diseases, including the development of new viral-based gene therapies , Barron’s reports.
This includes new Phase III trial data for Kerendia (finerenone) in patients with heart failure that was presented recently at this year’s European Society of Cardiology (ESC) Congress 2024. Dr. Perkins has also led the development and implementation of innovative digital educational outreach campaigns for primary care physicians.
Myocardial infarction is an ischemic disease in which a coronary artery supplying blood to the heart muscle is stenotic or obstructed, resulting in cardiac tissue necrosis. Due to the irreversible loss of cardiomyocytes, damaged heart tissue cannot be naturally regenerated.
Further efforts are urgently needed to increase diversity in the cardiology workforce, which will improve clinical trial diversity and cardiovascular health for all. Approaches from the whole scientific community to tackle the inequality in workforce, trial leadership and trial participants have to be developed.
Madrid, Spain – 22 May 2022: Levels of alcohol consumption currently considered safe by some countries are linked with development of heart failure, according to research presented at Heart Failure 2022, a scientific congress of the European Society of Cardiology (ESC).1
Identifying early risks and treatments among children and mothers, continued health disparities and finding new ways to use medications already on the market are among some of the significant scientific researchdevelopments in the fight against heart disease and stroke that emerged in 2022.
In a new study by researchers from Mass General Brigham's founding members, Brigham and Women's Hospital and Massachusetts General Hospital, a team extensively investigated the immune response of 16 adolescents and young adults who developed myocarditis after receipt of the COVID mRNA vaccine.
Tools for clinicians in point-of-care use UTICA, NY — More than 2 million coronary artery stents are implanted each year to help protect or restore normal blood flow to the heart, to treat patients suffering from angina or a heart attack due to coronary artery disease (CAD). While stents are highly effective and safe devices, […].
Experts from Servier and Genuity Science recently spoke on a webinar about using genomics data to drive drug development in heart failure and identify new targets for novel therapeutics. The reverse could also be true whereby the development of coronary artery disease may impact heart rate. HFrEF vs. HFpEF.
Sophia Antipolis – 19 March 2022: Women are less likely to receive lifesaving treatment for cardiogenic shock than men, according to research presented today at ESC Acute CardioVascular Care 2022, a scientific congress of the European Society of Cardiology (ESC).1
Velocity Clinical Research, the leading multi-specialty clinical sites business, announced it has expanded into Poland, acquiring its first site, ClinMedica Research. The site is recognized as one of the best research facilities in the country by Sponsors and contract research organizations (CROs).
New USDA-NIFA funding brings together research, academics, and Extension to improve knowledge, access, and self-monitoring skills for hypertension management Credit: Edwin Remsberg, University of Maryland To address the significant health burden of hypertension (characterized by consistently high blood pressure), the University of Maryland (UMD) was (..)
Beijing, China 19 Oct 2020: Elevated birth weight is linked with developing atrial fibrillation later in life, according to research presented at the 31st Great Wall International Congress of Cardiology (GW-ICC). Faculty from the European Society of Cardiology (ESC) will participate in joint scientific […].
But Dr Craig Granowitz, chief scientific officer of cardiology drug developer Amarin, says that this is only the tip of the iceberg when it comes to the devastating impact of CVD on global populations. “In One of the key takeaways from COVID has been the importance of the endothelial cell – the lining of the blood vessel.
Researchers at the University of Southern California Alfred E. Mann Department of Biomedical Engineering have developed a "heart attack on a chip," a device that could one day serve as a testbed to develop new heart drugs and even personalized medicines.
This expanded clinical research opportunities for patients as a core pillar of the affiliation’s mission, with the goal of providing access to novel treatments for diagnoses in addition to standard of care. An action plan was developed, with steps taken to address clinical research awareness gaps from an institutional perspective.
DCP developed an EHR-based workflows and integrated workflows within the local VA primary care setting. DCP developed 3 electronic workflows with 6 major configurations including applications needed outside of the EHR system. DCP developed a patient tracking tool that nurses could use to make sure patients got through each step.
Velocity recently convened more than 40 leaders from around the world for a summit on Councils to Accelerate Research Excellence (CARE). The summit focused on Velocity’s Diabetes + Obesity, MASH, Vaccine, Cardiology, and Women’s Health CARE Councils, along with a few areas in development.
A research team led by Prof. They have developed a non-invasive radio frequency (RF)-based system capable of monitoring heart rate variability (HRV) with clinical-grade accuracy over extended periods. Chen Yan at the University of Science and Technology of China (USTC) has taken a leap forward in cardiovascular health monitoring.
The five new NIHR National Patient Recruitment Centres (NPRCs) are set to shape the future of commercial clinical trials in the UK by offering new ways to conduct late-phase, large-scale research projects. The webinar will also cover: What the NPRCs’ franchise model means for research delivery.
Chief Executive Officer, Alexion , said: “For nearly 30 years Alexion has worked to develop and deliver transformative medicines to patients around the world with rare and devastating diseases. More recently, AstraZeneca has increased its efforts in immunology research and the development of medicines for immune-mediated diseases.
A Korea Institute of Science and Technology (KIST) research team has developed a novel stent surface treatment technology using laser patterning. This technology promotes endothelial cell growth while inhibiting smooth muscle cell dedifferentiation in blood vessels.
Credit: Mark Bauer/FSU College of Medicine Nearly a half-million people a year die from sudden cardiac death (SCD) in the U.S. — the result of malfunctions in the heart’s electrical system.
Women who have high blood pressure before they become pregnant may be twice as likely as those who don't to develop cardiovascular disease within a decade of giving birth, new research finds.
Baynes, head of Global Clinical Development (GCD) and Chief Medical Officer, Merck Research Laboratories (MRL), will be retiring from Merck in July. Li, president, Merck Research Laboratories, until his retirement. He also led the expansion of Merck’s research and development in China and Japan. “It
With heart disease the most common cause of death worldwide, researchers have attempted to quantify how cumulative exposure to multiple risk factors, like high blood pressure, obesity, and elevated cholesterol, affect an individual's risk of having a heart attack or stroke.
An algorithm developed using artificial intelligence could soon be used by doctors to diagnose heart attacks with better speed and accuracy than ever before, according to new research from the University of Edinburgh published in Nature Medicine.
The risk of developing cardiovascular disease is lower in people with obesity who have a genetic predisposition for high BMI than people with obesity influenced mainly by environmental factors such as lifestyle, researchers from Karolinska Institutet report in eClinicalMedicine.
“Without clinical research, there would be little if any development of new medicines,” says Isabelle Schenkenberger, MD. I’m proud and excited to be a part of it.” Dr. Schenkenberger is especially proud of her clinical trial research work in heart health, noting most new drugs never make it to market.
Sophia Antipolis – 28 June 2021: A study in more than 200,000 individuals has found that patients with heart failure are more likely to develop cancer compared to their peers without heart failure.
Researchers led by Northwestern University and the University of Texas at Austin (UT) have developed the first cardiac implant made from graphene, a two-dimensional super material with ultra-strong, lightweight and conductive properties.
Researchers have developed a new tool and technique that uses "vortex ultrasound"—a sort of ultrasonic tornado—to break down blood clots in the brain. The new approach worked more quickly than existing techniques to eliminate clots formed in an in vitro model of cerebral venous sinus thrombosis (CVST).
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content